Search Results

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change […]

The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1 Platinum-based chemotherapy had long been the standard of care in patients with advanced or recurrent endometrial cancer. New approaches to the classification of endometrial cancer based […]

The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. Across GI tumour types, enhanced efficacy has been seen when these agents are used in […]

Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]

Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022. GALAXY study in CIRCULATE-Japan abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.009  Clinical trial information: jRCT1031200006 RESPECT study abstract: https://meetings.asco.org/abstracts-presentations/204531 Clinical Trial Registration Number: UMIN000008866 GERCOR NIPICOL study abstract: […]

Cumulatively, TNBC accounts for 35–40% of breast cancer deaths in the United States, despite only comprising 10–15% of total breast cancer cases diagnosed.1 Even before the use of anti-estrogen therapies became widespread, hormone receptor-positive breast cancer (HR+BC) provided a far more favourable risk of recurrence and overall prognosis compared with TNBC.2,3 Once metastatic, TNBC historically carries […]

touchONCOLOGY joins Dr Alexander Spira (Virginia Cancer Specialists, Fairfax, VA, USA) at WCLC 2021 to discuss the current, ongoing PERLA phase II clinical trial, that explores the efficacy of dostarlimab + chemotherapy versus pembrolizumab + chemotherapy in metastatic non-squamous non-small cell lung cancer. ClinicalTrials.gov Identifier: NCT04581824  Questions 1. What are the potential advantages of dostarlimab […]

Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]